Impact of smoking history on the efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutations
S Igawa, J Sasaki, S Otani, M Ishihara, A Takakura… - Oncology, 2015 - karger.com
Background: Gefitinib treatment has come to be recognized as the standard therapy for
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
Gefitinib is effective in treating advanced non-small cell lung cancer (NSCLC), especially in
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non–small-cell lung cancer with epidermal growth factor receptor gene …
A Inoue, T Suzuki, T Fukuhara, M Maemondo… - Journal of Clinical …, 2006 - ascopubs.org
Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …
Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of …
T Shukuya, T Takahashi, R Kaira, A Ono… - Cancer …, 2011 - Wiley Online Library
The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - Elsevier
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer
Purpose Gefitinib is safe for the treatment of non-small cell lung cancer (NSCLC), but some
patients experience toxicities and require dose reduction. The purpose of this study was to …
patients experience toxicities and require dose reduction. The purpose of this study was to …
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …
N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - Elsevier
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation
S Igawa, M Kasajima, M Ishihara, M Kimura, Y Hiyoshi… - Oncology, 2014 - karger.com
Background: Exon 19 deletion and L858R point mutation of the epidermal growth factor
receptor (EGFR) are the most commonly encountered EGFR mutations in non-small cell …
receptor (EGFR) are the most commonly encountered EGFR mutations in non-small cell …
Tumor burden is predictive of survival in patients with non–small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib
Background Although activating epidermal growth factor receptor (EGFR) mutations are
excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most …
excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most …
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
S Morita, I Okamoto, K Kobayashi, K Yamazaki… - Clinical Cancer …, 2009 - AACR
Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …
associated with an increased response to gefitinib in patients with non–small cell lung …